title: Histamine H3 receptor activation prevents dopamine D1 receptor-mediated inhibition of dopamine release in the rat striatum: a microdialysis study.
abstract: Histamine H3 receptors (H3Rs) co-localize with dopamine (DA) D1 receptors (D1Rs) on striatal medium spiny neurons and functionally antagonize D1R-mediated responses. The intra-striatal administration of D1R agonists reduces DA release whereas D1R antagonists have the opposite effect. In this work, a microdialysis method was used to study the effect of co-activating D1 and H3 receptors on the release of DA from the rat dorsal striatum. Infusion of the D1R agonist SKF-38393 (0.5 and 1 μM) significantly reduced DA release (26-58%), and this effect was prevented by co-administration of the H3R agonist immepip (10 μM). In turn, the effect of immepip was blocked by the H3R antagonist thioperamide (10 μM). Our results indicate that co-stimulation of post-synaptic D1 and H3 receptors may indirectly regulate basal DA release in the rat striatum and provide in vivo evidence for a functional interaction between D1 and H3 receptors in the basal ganglia.
authors.affiliation: Departamento de Neurorrehabilitación, Instituto Nacional de Rehabilitación, SSA, Mexico.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Alfaro-Rodriguez
authors.forename: María
authors.initials: M
authors.lastname: Alonso-Spilsbury
authors.forename: Emilio
authors.initials: E
authors.lastname: Arch-Tirado
authors.forename: Rigoberto
authors.initials: R
authors.lastname: Gonzalez-Pina
authors.forename: José-Antonio
authors.initials: JA
authors.lastname: Arias-Montaño
authors.forename: Antonio
authors.initials: A
authors.lastname: Bueno-Nava
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology; D004347:Drug Interactions; D017442:Histamine Agonists / Q000008:administration & dosage / Q000494:pharmacology; D054828:Histamine H3 Antagonists / Q000494:pharmacology*; D007093:Imidazoles / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008297:Male; D017551:Microdialysis; D008845:Microinjections; D010880:Piperidines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D018100:Receptors, Histamine H3 / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
chemical_list: D018491:Dopamine Agonists; D017442:Histamine Agonists; D054828:Histamine H3 Antagonists; D007093:Imidazoles; D010880:Piperidines; D017447:Receptors, Dopamine D1; D018100:Receptors, Histamine H3; C085755:4-(1H-imidazol-4-ylmethyl)piperidine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C052075:thioperamide; D004298:Dopamine
keywords: D(1) receptor; D(1)R; D(2)R; DA; Dopamine; Dopamine release; H(3) receptor; H(3)R; Histamine; MSNs; Striatum; dopamine; dopamine D(1) receptor; dopamine D(2) receptor; histamine H(3) receptor; medium spiny neurons